ERBB2 and breast cancer: PARP inhibitors are currently indicated as treatment for BRCA-mutated (BRCAmut) OC and HER2- BC, as well as maintenance treatment for OC after response to platinum-based chemotherapy, regardless of BRCAmut [5–7].